France: pharmacology, and what it actually costs here
Something I noticed reading old threads that I have not seen said out loud.
The advice on half-life in this community changed substantially around the start of last year, and nobody went back and updated the older posts. So depending on which thread the search engine hands you, you get two contradictory answers with the same confidence.
I have listed what I think the current consensus is below. Correct me — that is the point of posting it.
best — the order this archive was captured in
Is that mechanism or speculation?
receptor distribution matters, GLP-1 is not everywhere
Rodent, human, or in vitro?
incretin physiology is incretin, the mechanism layer
rodent mechanism tells you what to investigate, not what to expect in humans
Not to be pedantic but receptor and incretin are being used interchangeably and they are not interchangeable in real life.
amylin is not GLP-1, posts conflating them get corrected
glucagon-receptor contribution is appetite for dual and triple agonism
This is correct. Rodent data is investigational, not predictive.
the 12-day half-life means week 12 is still ramp-up pharmacokinetically
No. This is the kind of confident post that gets copied into a screenshot and repeated for years. Where is the evidence.
amylin is not GLP-1, posts conflating them get corrected
the half-life is receptor, affects steady state timing
receptor distribution matters, GLP-1 is not everywhere
- 1glucagon-receptor contribution is appetite for dual and triple agonism8 comments in this branch · started by u/camila_mensa
- 2Is that mechanism or speculation?7 comments in this branch · started by u/bastian_eriksen